Skip to main content
    A

    Aurinia Pharmaceuticals Inc (AUPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.73
    +0.12 (+0.72%)

    Market Cap: $2.18B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    67%(26/39)
    Avg Surprise
    +18.83%
    Streak
    10 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.22
    Range$0.21 - $0.25
    5 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate DriftChange to current
    90d ago$0.24-9.3%
    60d ago$0.24-9.3%
    30d ago$0.24-9.3%
    7d ago$0.24-7.6%
    Current$0.22
    Revenue Consensus
    $83M
    Range$80M - $87M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.29
    Range$0.24 - $0.35
    5 analysts
    Revenue Consensus
    $88M
    Range$82M - $96M
    7 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.29---
    Sep 26EST
    		-$0.22---
    Jun 26
    Reported Aug 6
    		$0.28$0.18+55.56%Beat+75.0%
    Mar 26
    Reported May 7
    		$0.25$0.16+56.25%Beat+56.3%
    Dec 25
    Reported Feb 26
    		$0.26$0.21+23.81%Beat+2500.0%
    Sep 25
    Reported Nov 4
    		$0.23$0.16+43.75%Beat+130.0%
    Jun 25
    Reported Jul 31
    		$0.16$0.15+6.67%Beat+1500.0%
    Mar 25
    Reported May 12
    		$0.16$0.10+60.00%Beat+328.6%
    Dec 24
    Reported Feb 27
    		$0.01$-0.02+162.50%Beat+105.3%
    Sep 24
    Reported Nov 7
    		$0.10$0.02+400.00%Beat+211.1%
    Jun 24
    Reported Aug 1
    		$0.01$0.01+0.00%Beat+112.5%
    Mar 24
    Reported May 2
    		$-0.07$-0.14+50.00%Beat+61.1%
    Dec 23
    Reported Feb 15
    		$-0.19$-0.16-18.75%Miss-5.6%
    Sep 23
    Reported Nov 2
    		$-0.09$-0.17+47.06%Beat-50.0%
    Jun 23
    Reported Aug 3
    		$-0.08N/A+57.89%Beat+68.0%
    Mar 23
    Reported May 4
    		$-0.18$-0.22+18.18%Beat+33.3%
    Dec 22
    Reported Feb 28
    		$-0.18$-0.27+33.33%Beat+28.0%
    Sep 22
    Reported Nov 3
    		$-0.06N/A+68.42%Beat+84.6%
    Jun 22
    Reported Aug 4
    		$-0.25$-0.22-13.64%Miss+32.4%
    Mar 22
    Reported May 10
    		$-0.27$-0.27+0.00%Beat+32.5%
    Dec 21
    Reported Feb 28
    		$-0.25$-0.27+7.41%Beat-400.0%
    Sep 21
    Reported Nov 3
    		$-0.39$-0.33-18.18%Miss-30.0%
    Jun 21
    Reported Aug 5
    		$-0.37$-0.36-2.78%Miss-42.3%
    Mar 21
    Reported May 6
    		$-0.40$-0.38-5.26%Miss-73.9%
    Dec 20
    Reported Feb 24
    		$-0.05N/A+79.17%Beat+93.6%
    Sep 20
    Reported Nov 10
    		$-0.30$-0.24-25.00%Miss-42.9%
    Jun 20
    Reported Aug 11
    		$-0.26$-0.24-8.33%Miss-52.9%
    Mar 20
    Reported May 14
    		$-0.23$-0.34+32.35%Beat-43.8%
    Dec 19
    Reported Mar 5
    		$-0.78$-0.21-271.43%Miss-358.8%
    Sep 19
    Reported Nov 14
    		$-0.21$-0.18-16.67%Miss+0.0%
    Jun 19
    Reported Aug 6
    		$-0.17$-0.17+0.00%Beat-6.3%
    Mar 19
    Reported May 14
    		$-0.16$-0.18+11.11%Beat-6.7%
    Dec 18
    Reported Jan 22
    		$-0.17$-0.18+5.56%Beat-325.0%
    Sep 18
    Reported Nov 8
    		$-0.21$-0.19-10.53%Miss-31.2%
    Jun 18
    Reported Aug 9
    		$-0.16$-0.17+5.88%Beat-33.3%
    Mar 18
    Reported May 10
    		$-0.15$-0.17+11.76%Beat+25.0%
    Dec 17
    Reported Mar 15
    		$-0.04N/A+71.43%Beat+81.0%
    Sep 17
    Reported Nov 14
    		$-0.16$-0.12-33.33%Miss-
    Jun 17
    Reported Aug 10
    		$-0.12$-0.13+7.69%Beat-
    Mar 17
    Reported May 15
    		$-0.20$-0.12-66.67%Miss-
    Dec 16
    Reported Jan 3
    		$-0.21$-0.11-90.91%Miss-

    Key Metrics

    Valuation
    P/E Ratio16.40EV/EBITDA12.40x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin100.80%Operating Margin55.70%
    ROE66.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage36.71x
    Current Ratio5.42xQuick Ratio4.97x
    Trading Statistics
    Beta1.61Avg Volume865.82K
    52-Week High$19.2552-Week Low$11.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$16.24
    SMA 20$16.35
    SMA 50$16.22
    SMA 200$15.57
    EMA 10$16.41
    EMA 20$16.34
    EMA 50$16.21
    EMA 200$15.29

    MACD

    Line: 0.07Signal: 0.02Hist: 0.05

    ADX

    ADX: 21.6+DI: 31.1-DI: 15.0

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down72.0
    PSAR$15.50

    Bollinger Bands

    Upper Band$17.06
    Lower Band$15.65
    %B Position858%(Upper)
    Band Width0.77

    RSI (14-Day)

    Neutral
    58.1

    Momentum Oscillators

    Stoch %K68.1
    Stoch %D69.1
    Williams %R-31.0
    ROC (10d)4.9%
    Momentum0.78
    CCI (20d)125.0
    MFI (14d)39.1

    Volatility Measures

    ATR (14d)$0.47(2.8%)
    StdDev (20d)0.35
    Hist Vol20.4%(Moderate)

    Volume Flow

    VWAP$16.91
    OBV47.4M
    AD Line20.0M
    CMF (20d)-0.094

    Volume Metrics

    Avg Vol (20d)851.3K
    Vol Ratio1.2x
    VWMA (20d)$16.38

    Pivot Points

    R3$17.63
    R2$17.22
    R1$16.92
    Pivot Point$16.51
    S1$16.21
    S2$15.80
    S3$15.49

    Advanced Oscillators

    TSI4.76
    Ultimate Osc55.8
    KST-3.74

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$83.22M$77.70M$77.11M$73.47M$70.01M$62.47M$59.87M$67.77M$57.19M$50.30M$45.09M$54.52M
    Cost of Revenue$6.55M$6.50M$8.80M$8.18M$7.12M$8.57M$5.55M$6.04M$8.91M$7.75M$5.39M$6.77M
    Gross Profit$76.67M$71.20M$68.31M$65.29M$62.89M$53.89M$54.31M$61.74M$48.28M$42.55M$39.70M$47.75M
    Operating Expenses$30.32M$29.78M$35.08M$35.55M$42.81M$32.04M$55.98M$49.99M$49.80M$55.80M$69.37M$64.01M
    R&D$13.05M$7.47M$10.89M$8.44M$7.43M$5.74M$8.11M$3.05M$4.08M$5.55M$10.23M$13.61M
    SG&A$23.51M$22.03M$29.25M$26.18M$26.02M$20.34M$37.03M$42.37M$44.93M$47.70M$50.07M$47.76M
    Operating Income$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M$-1,669,000$11.75M$-1,513,000$-13,253,000$-29,674,000$-16,263,000
    Interest Income$3.39M$3.52M$3.50M$3.32M$3.19M$3.57M$3.99M$4.27M$4.19M$4.53M$4.57M$4.51M
    Interest Expense$948,000$1.01M$1.05M$1.10M$1.12M$1.07M$1.15M$1.21M$1.20M$1.28M$1.31M$1.40M
    Income Before Tax$48.79M$43.92M$35.69M$31.96M$22.16M$24.35M$1.17M$14.81M$1.48M$-10,010,000$-26,416,000$-13,149,000
    Income Tax Expense$11.37M$9.57M$-175,104,000$411,000$643,000$1.00M$-256,000$457,000$756,000$739,000$459,000$298,000
    Net Income$37.41M$34.35M$210.79M$31.55M$21.51M$23.34M$1.43M$14.35M$722,000$-10,749,000$-26,875,000$-13,447,000
    EBITDA$49.29M$43.92M$35.77M$31.98M$22.38M$24.05M$214,000$13.22M$205,000$-11,612,000$-28,030,000$-14,238,000
    EBIT$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M$-1,669,000$11.75M$-1,513,000$-13,253,000$-29,674,000$-16,263,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about AUPH

    News

    November 3 earnings carry USD 83.61 million estimate for Aurinia Pharmaceuticals stock

    Aurinia Pharmaceuticals is estimated to report third-quarter 2026 results on November 3, with an expected revenue of USD 83.61 million and earnings per share of USD 0.22. This revenue estimate represents a 13.80 percent...

    ad-hoc-news.de•10/15/26•Neutral

    Aurinia Pharmaceuticals plots early exit from Montgomery County lease following leadership overhaul

    Aurinia Pharmaceuticals is reportedly planning an early departure from its Montgomery County lease after a recent leadership change. The company's new CEO, Kevin Tang, who took over in March...

    The Business Journals•10/8/26•Somewhat-Bearish

    Aurinia Pharmaceuticals stock heads toward its November 3 report

    Aurinia Pharmaceuticals is preparing for its third-quarter 2026 earnings report on November 3, 2026. The company exceeded Q2 2026 expectations with USD 0.28 EPS and USD 83.2 million in revenue...

    AD HOC NEWS•10/7/26•Bullish

    Aurinia reports second-quarter profit growth: what it means for Aurinia Pharmaceuticals stock

    Aurinia Pharmaceuticals reported a significant 74% increase in second-quarter net income to $37.40 million, with total revenue up 19% to $83.20 million...

    AD HOC NEWS•10/7/26•Bullish

    Aurinia Pharmaceuticals (NASDAQ: AUPH) Chief Legal Officer Stephen P. Robertson Disposes 11,939 Shares at $15.95 on September 10, 2026

    Aurinia Pharmaceuticals' Chief Legal Officer, Stephen P. Robertson, sold 11,939 shares of the company's stock at $15.95 per share on September 10, 2026. This transaction reduced his stake by approximately 2.0%...

    Kalkine Media•9/14/26•Somewhat-Bearish

    AUPH Valuation and Fair Value

    P/E
    16.4x
    Forward P/E
    11.8x
    EV/EBITDA
    12.4x
    PEG
    0.0x
    P/B
    3.5x
    See GNG's fair value

    AUPH Profitability: Margins, ROIC and FCF

    Gross margin
    90.4%
    Operating margin
    55.7%
    Net margin
    100.8%
    ROE
    66.1%
    FCF margin
    56.2%

    AUPH Competitors

    CompanyTicker
    Harmony Biosciences HoldingsHRMY
    Disc Medicine Inc.IRON
    Celldex Therapeutics IncCLDX
    Progyny IncPGNY
    NeoGenomics IncNEO
    Dynavax Technologies CorporationDVAX
    Bausch Health Companies IncBHC
    Pharvaris BVPHVS

    Sector: Healthcare

    AUPH Analyst Ratings

    Consensus
    Buy
    Analysts
    7
    Strong Buy
    0
    Buy
    4
    Hold
    3
    Sell
    0
    Strong Sell
    0

    AUPH Bull Case vs Bear Case

    Bull case

    • AUPH converts 56.2% of revenue into free cash flow.
    • AUPH has a 100.8% net profit margin.
    • AUPH beat EPS estimates in 100.0% of its last 8 reported quarters.

    AUPH Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    101.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.22
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 0 down

    Frequently Asked Questions About AUPH

    Does AUPH pay dividends?

    Aurinia Pharmaceuticals Inc (AUPH) does not currently pay a regular dividend.

    What is AUPH's P/E ratio?

    Aurinia Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 16.40.

    What is AUPH's market cap?

    Aurinia Pharmaceuticals Inc (AUPH) has a market capitalization of $2.18B with a current stock price of $16.73.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In